About this policy
This article addresses comments received by CGS Administrators on the proposed policy addressing allogeneic HCT for primary refractory or relapse of Hodgkin's or non-Hodgkin's lymphoma with B-cell or T-cell origin presented at Open Meeting on October 25 and 26, 2022.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.